ProfessorBobBrown

Faculty of Medicine, Department of Surgery & Cancer

Senior Research Investigator

Contact

+44 (0)20 7594 1804b.brown Website

Assistant

Ms Sophie Lions +44 (0)20 7594 2792

Location

1 007Institute of Reproductive and Developmental BiologyHammersmith Campus

Summary

Professor Robert (Bob) Brown is Chair in Translational Oncology in the Department of Surgery and Cancer within the Faculty of Medicine at Imperial College. His post is a joint appointment between Imperial College London and Institute of Cancer Research where he is Professor of Translational Oncology in the Section of Medicine.

Professor Brown’s work focuses on epigenetics, patient stratification and drug resistance research, with a particular focus on ovarian cancer. He facilitates development of compounds which can reverse epigenetic silencing and is using molecular biomarker assays to aid the preclinical development and clinical use of these compounds. Recent research interests include the effect of DNA damaging agents on the epigenome, epigenetic targeting using CRISPR and whether systems oncology approaches can be used to monitor and stratify patients for targeted treatments.

Selected Publications

Journal Articles

Flanagan JM, Wilson A, Koo C, et al.Flanagan JM, Wilson A, Koo C, Masrour N, Gallon J, Loomis E, Flower K, Wilhelm-Benartzi C, Hergovich A, Cunnea P, Gabra H, Braicu EI, Sehouli J, Darb-Esfahani S, Vanderstichele A, Vergote I, Kreuzinger C, Cacsire Castillo-Tong D, Wisman GB, Berns EM, Siddiqui N, Paul J, Brown R close, 2017, Platinum-based chemotherapy induces methylation changes in blood DNA associated with overall survival in ovarian cancer patients, Clinical Cancer Research, Vol:23, ISSN:1557-3265, Pages:2213-2222

Bonito NA, Borley J, Wilhelm-Benartzi CS, et al.Bonito NA, Borley J, Wilhelm-Benartzi CS, Ghaem-Maghami S, Brown R close, 2016, Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer., Clinical Cancer Research, Vol:22, ISSN:1557-3265, Pages:3097-3104

Curry E, Green I, Chapman-Rothe N, et al.Curry E, Green I, Chapman-Rothe N, Shamsaei E, Kandil S, Cherblanc F, Payne L, Bell E, Ganesh T, Srimongkolpithak N, Caron J, Li F, Uren AG, Snyder JP, Vedadi M, Fuchter MJ, Brown R close, 2015, Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells, Clinical Epigenetics, Vol:7, ISSN:1868-7083

Patch A-M, Christie EL, Etemadmoghadam D, et al.Patch A-M, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MCJ, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS, Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew Y-E, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O'Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller DK, Arnau GM, Tothill RW, Holloway TP, Semple T, Harliwong I, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner TJC, Christ AN, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor DF, Xu Q, Fink JL, Waddell N, Drapkin R, Stronach E, Gabra H, Brown R, Jewell A, Nagaraj SH, Markham E, Wilson PJ, Ellul J, McNally O, Doyle MA, Vedururu R, Stewart C, Lengyel E, Pearson JV, Waddell N, deFazio A, Grimmond SM, Bowtell DDL close, 2015, Whole-genome characterization of chemoresistant ovarian cancer, Nature, Vol:521, ISSN:0028-0836, Pages:489-494

Brown R, Curry E, Magnani L, et al.Brown R, Curry E, Magnani L, Wilhelm-Benartzi CS, Borley J close, 2014, Poised epigenetic states and acquired drug resistance in cancer, Nature Reviews Cancer, Vol:14, ISSN:1474-1768, Pages:747-753

More Publications